1. Home
  2. KSPI vs BGNE Comparison

KSPI vs BGNE Comparison

Compare KSPI & BGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KSPI
  • BGNE
  • Stock Information
  • Founded
  • KSPI 2008
  • BGNE 2010
  • Country
  • KSPI Kazakhstan
  • BGNE Cayman Islands
  • Employees
  • KSPI N/A
  • BGNE N/A
  • Industry
  • KSPI
  • BGNE Biotechnology: Pharmaceutical Preparations
  • Sector
  • KSPI
  • BGNE Health Care
  • Exchange
  • KSPI Nasdaq
  • BGNE Nasdaq
  • Market Cap
  • KSPI 21.1B
  • BGNE 21.0B
  • IPO Year
  • KSPI 2024
  • BGNE 2016
  • Fundamental
  • Price
  • KSPI $106.17
  • BGNE $194.26
  • Analyst Decision
  • KSPI Strong Buy
  • BGNE Buy
  • Analyst Count
  • KSPI 4
  • BGNE 7
  • Target Price
  • KSPI $151.75
  • BGNE $247.07
  • AVG Volume (30 Days)
  • KSPI 188.3K
  • BGNE 298.2K
  • Earning Date
  • KSPI 10-18-2024
  • BGNE 11-12-2024
  • Dividend Yield
  • KSPI 6.93%
  • BGNE N/A
  • EPS Growth
  • KSPI 24.38
  • BGNE N/A
  • EPS
  • KSPI 10.55
  • BGNE N/A
  • Revenue
  • KSPI $4,933,314,249.00
  • BGNE $3,351,304,621.00
  • Revenue This Year
  • KSPI $22.99
  • BGNE $969.39
  • Revenue Next Year
  • KSPI $19.51
  • BGNE $24.79
  • P/E Ratio
  • KSPI $10.41
  • BGNE N/A
  • Revenue Growth
  • KSPI 37.64
  • BGNE 50.22
  • 52 Week Low
  • KSPI $85.02
  • BGNE $126.97
  • 52 Week High
  • KSPI $143.72
  • BGNE $248.16
  • Technical
  • Relative Strength Index (RSI)
  • KSPI 41.83
  • BGNE 39.84
  • Support Level
  • KSPI $109.33
  • BGNE $184.49
  • Resistance Level
  • KSPI $114.98
  • BGNE $209.29
  • Average True Range (ATR)
  • KSPI 3.24
  • BGNE 6.14
  • MACD
  • KSPI -0.45
  • BGNE -1.37
  • Stochastic Oscillator
  • KSPI 1.61
  • BGNE 37.53

About KSPI Joint Stock Company Kaspi.kz

Kaspi.kz JSC is the payment, marketplace, and Fintech ecosystem in Kazakhstan. The firm provides interconnected technologically seamless products and services that help people to pay, shop, and manage their finances. Its operating segment includes the Payments Platform that connects its customers, which consist of both consumers and merchants, to facilitate cashless, digital transactions, the Marketplace Platform that connects merchants and consumers enabling merchants to increase their sales and consumers to buy a broad selection of products and services offered by a variety of merchants, and Fintech Platform that enables customers to manage their personal finances online and access consumer finance and deposit products through the Kaspi.kz Super App.

About BGNE BeiGene Ltd.

BeiGene Ltd is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. BeiGene's key cancer treatments are BRUKINSA (zanubrutinib), Bruton's tyrosine kinase (BTK) inhibitor, and TEVIMBRA (tislelizumab), an anti-PD-1 antibody. In addition, it has a diverse pipeline of novel therapeutics focusing on a range of malignancies, including AML, MDS, multiple myeloma, lung, gastrointestinal, breast, and gynecologic cancers. The Company operates in one segment: pharmaceutical products and is primarily located in the U.S. and the PRC. Key revenue is generated from the U.S.

Share on Social Networks: